Clinical Trials Browser

Tuberous Sclerosis × Cannabidiol × Clear all

NCT05864846 2026-04-27

EpiCom

Phase 4 Completed

Behavior, Seizures, Tuberous Sclerosis

NCT05044819 2026-04-22

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Phase 4 Active not recruiting

Epilepsies, Myoclonic, Liver Cirrhosis, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT05485831 2026-02-17

EpiTALY

Epilepsies, Myoclonic, Seizures, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT04485104 2025-10-31

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Phase 3 Terminated

3 enrolled 28 charts

Tuberous Sclerosis 1, Tuberous Sclerosis 2, Epilepsy, Epilepsies, Myoclonic, Seizures, Spasms, Infantile, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT02544763 2022-09-28

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Phase 3 Completed

224 enrolled 18 charts

Seizures, Tuberous Sclerosis

NCT02544750 2022-07-14

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Phase 3 Completed

199 enrolled 14 charts

Seizures, Tuberous Sclerosis